hereditary 发表于 2025-3-23 11:26:31

http://reply.papertrans.cn/1/48/4787/4787-11.png

chronology 发表于 2025-3-23 15:11:40

Submitted on: 16 August 2019.
Revised on: 16 October 2019.
Accepted on: 09 November 2019.

___________________Cardiovascular Therapeutics---WILEY-HINDAWI

conceal 发表于 2025-3-23 18:24:01

http://reply.papertrans.cn/1/48/4787/4787-13.png

reptile 发表于 2025-3-24 00:27:03

http://reply.papertrans.cn/1/48/4787/4787-14.png

Allergic 发表于 2025-3-24 04:21:02

Submitted on: 08 October 2004.
Revised on: 22 November 2004.
Accepted on: 18 January 2005.

___________________Cardiovascular Therapeutics---WILEY-HINDAWI

Medicare 发表于 2025-3-24 09:13:25

http://reply.papertrans.cn/1/48/4787/4787-16.png

CHOP 发表于 2025-3-24 13:47:22

http://reply.papertrans.cn/1/48/4787/4787-17.png

watertight, 发表于 2025-3-24 16:58:50

http://reply.papertrans.cn/1/48/4787/4787-18.png

peritonitis 发表于 2025-3-24 22:29:17

http://reply.papertrans.cn/1/48/4787/4787-19.png

有害处 发表于 2025-3-25 01:34:17

http://reply.papertrans.cn/1/48/4787/4787-20.png
页: 1 [2] 3 4
查看完整版本: SCIE期刊Cardiovascular Therapeutics 2024/2025影响因子:3.404 (CARDIOVASC THER) (1755-5914). (PHARMACOLOGY & PHARMACY)(药理学与药学)S